This study is to evaluate the efficacy and safety that the occurrence of incontinence is significantly decrease using the propiverine hydrochloride for 200 female patients with mixed (stress and urge) urinary incontinence in one week during a twelve-week treatment period.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
62
Administrate Propiverine Hydrochloride for 12 weeks
Shinshu University Hospital
Matsumoto, Nagano, Japan
Occurrence of incontinence
Change in occurrence of incontinence during a twelve-week treatment
Time frame: during a twelve-week treatment period
The number of protective pad used
Change in the number of protective pad used during a twelve-week treatment period
Time frame: during a twelve-week treatment period
Reduction ratio of the occurrence for incontinence
Change in reduction ratio of the occurrence for incontinence during a twelve-week treatment period
Time frame: during a twelve-week treatment period
ICIQ-Short Form(SF) scores
Change in ICIQ-SF scores during a twelve-week treatment period
Time frame: during a twelve-week treatment period
I-QOL scores
Change in I-QOL scores during a twelve-week treatment period
Time frame: during a twelve-week treatment period
IPSS-QOL scores
Change in IPSS-QOL scores during a twelve-week treatment period
Time frame: during a twelve-week treatment period
IPSS symptom scores
Change in IPSS symptom scores during a twelve-week treatment period
Time frame: during a twelve-week treatment period
OABSS symptom scores
Change in OABSS symptom scores during a twelve-week treatment period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: during a twelve-week treatment period
Blood pressure
Change in blood pressure during a twelve-week treatment period
Time frame: during a twelve-week treatment period
Pulse rate
Change in pulse rate during a twelve-week treatment period
Time frame: during a twelve-week treatment period
Safety assessment
The occurrence of adverse events during a twelve-week treatment period
Time frame: during a twelve-week treatment period